利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.042 秒)

    Indazole-derivatives as factor Xa inhibitors
    22.
    发明授权
    Indazole-derivatives as factor Xa inhibitors 有权
    吲唑衍生物作为因子Xa抑制剂

    公开(公告)号：US07365088B2

    公开(公告)日：2008-04-29

    申请号：US10849088

    申请日：2004-05-19

    申请人： Marc Nazare ,  Volkmar Wehner ,  Volker Laux ,  Matthias Urmann ,  Armin Bauer ,  Hans Matter

    发明人： Marc Nazare ,  Volkmar Wehner ,  Volker Laux ,  Matthias Urmann ,  Armin Bauer ,  Hans Matter

    IPC分类号： A16K31/42 ,  A16K31/4152 ,  C07D261/20 ,  C07D413/14

    CPC分类号： C07D413/14 ,  C07D401/12 ,  C07D401/14

    摘要： The present invention relates to a compound of the formula I wherein J1, J2, R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 本发明涉及式I化合物，其中J 1，J 2，R 0，R 1，O 2， >，R 2，Q，V，G和M如本文所定义。 式I的化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用，并且适用于例如治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于存在因子Xa和/或因子VIIa的不期望活性或用于治愈 或预防因子Xa和/或因子VIIa的抑制。 本发明还涉及式I化合物的制备方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

    Azaindole-derivatives as factor Xa inhibitors
    23.
    发明授权
    Azaindole-derivatives as factor Xa inhibitors 有权
    Azaindole衍生物作为因子Xa抑制剂

    公开(公告)号：US07317027B2

    公开(公告)日：2008-01-08

    申请号：US10849089

    申请日：2004-05-19

    申请人： Marc Nazare ,  Volkmar Wehner ,  David William Will ,  Kurt Ritter ,  Matthias Urmann ,  Hans Matter

    发明人： Marc Nazare ,  Volkmar Wehner ,  David William Will ,  Kurt Ritter ,  Matthias Urmann ,  Hans Matter

    IPC分类号： A61K31/44 ,  C07D401/00

    CPC分类号： C07D471/04

    摘要： The present invention relates to compounds of the formula I wherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 本发明涉及式I化合物，其中R 0，R 1，R 2，R 3，R 3， ，Q，V，G和M如本文所定义。 式I的化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用，并且适用于例如治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于存在因子Xa和/或因子VIIa的不期望活性或用于治愈 或预防因子Xa和/或因子VIIa的抑制。 本发明还涉及式I化合物的制备方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

    Pyrrole-derivatives as factor Xa inhibitors
    24.
    发明授权
    Pyrrole-derivatives as factor Xa inhibitors 有权
    吡咯衍生物作为因子Xa抑制剂

    公开(公告)号：US07465806B2

    公开(公告)日：2008-12-16

    申请号：US11467277

    申请日：2006-08-25

    申请人： Armin Bauer ,  Michael Wagner ,  Marc Nazare ,  Volkmar Wehner ,  Matthias Urmann ,  Hans Matter

    发明人： Armin Bauer ,  Michael Wagner ,  Marc Nazare ,  Volkmar Wehner ,  Matthias Urmann ,  Hans Matter

    IPC分类号： C07D261/06 ,  C07D207/32

    CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D413/14

    摘要： The present invention relates to compounds of the formulae I and Ia, wherein R0; R1; R3; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae I and Ia are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ia, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 本发明涉及式I和Ia的化合物，其中R 0; R1; R3; R4; R22，Q; V，G和M具有权利要求中所示的含义。 式I和Ia的化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用，适用于治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于存在因子Xa和/或因子VIIa的不期望活性或用于治愈 或预防因子Xa和/或因子VIIa的抑制。 本发明还涉及制备式I和Ia化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

    Benzimidazole-derivatives as factor Xa inhibitors
    26.
    发明授权
    Benzimidazole-derivatives as factor Xa inhibitors 有权
    苯并咪唑衍生物作为因子Xa抑制剂

    公开(公告)号：US07741341B2

    公开(公告)日：2010-06-22

    申请号：US10849436

    申请日：2004-05-19

    申请人： Marc Nazare ,  Michael Wagner ,  Volkmar Wehner ,  Hans Matter ,  Matthias Urmann ,  Kurt Ritter

    发明人： Marc Nazare ,  Michael Wagner ,  Volkmar Wehner ,  Hans Matter ,  Matthias Urmann ,  Kurt Ritter

    IPC分类号： A61K31/4523 ,  C07D401/14 ,  C07D409/14

    CPC分类号： C07D235/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/08 ,  C07D495/04

    摘要： The present invention relates to compounds of the formula I, wherein R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 本发明涉及式I化合物，其中R 0，R 1，R 2，Q，V，G和M如本文所定义。 式I的化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用，并且适用于例如治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于存在因子Xa和/或因子VIIa的不期望活性或用于治愈 或预防因子Xa和/或因子VIIa的抑制。 本发明还涉及式I化合物的制备方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

    Beta-Aminoacid-Derivatives As Factor Xa Inhibitors
    27.
    发明申请
    Beta-Aminoacid-Derivatives As Factor Xa Inhibitors 审中-公开
    β-氨基酸衍生物作为因子Xa抑制剂

    公开(公告)号：US20070179122A1

    公开(公告)日：2007-08-02

    申请号：US11469513

    申请日：2006-09-01

    申请人： Matthias Urmann ,  Marc Nazare ,  Volkmar Wehner ,  Hans Matter ,  Armin Bauer ,  Michael Wagner

    发明人： Matthias Urmann ,  Marc Nazare ,  Volkmar Wehner ,  Hans Matter ,  Armin Bauer ,  Michael Wagner

    IPC分类号： A61K31/553 ,  A61K31/551 ,  A61K31/55 ,  A61K31/541 ,  A61K31/496 ,  A61K31/5377 ,  C07D417/02 ,  C07D413/02 ,  C07D403/02

    CPC分类号： C07K5/0202 ,  C07D265/32 ,  C07D265/33 ,  C07D291/06 ,  C07D295/112 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D419/12

    摘要： The present invention relates to compounds of the formula I, in which R0; R1; R2; R3; R4; R5, R, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboemboic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

    摘要翻译： 本发明涉及式I化合物，其中R 0， R＆lt; 1＆gt;; R 2; 3＆lt; 3＆gt; R 4; R 5，R，Q; V，G和M具有权利要求中所示的含义。 式I的化合物是有价值的药理活性化合物。 它们表现出强烈的抗血栓形成作用，并且适用于例如治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可用于存在因子Xa和/或因子VIIa的不期望活性或用于治愈 或预防因子Xa和/或因子VIIa的抑制。 本发明还涉及式I化合物的制备方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。